Skip to content
Relatix Bio

Relatix Bio

Radically different

  • Services
  • Knowledgebase
  • Partnerships
  • Our Approach
  • Contact
  • About
    • Vision
    • Our mission
    • Privacy Policy
    • FAQ
    • News
Posted on April 24, 2026 by admin

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

Nature Medicine, Published online: 23 April 2026; doi:10.1038/s41591-026-04415-5

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial

CategoriesImported News TagsClinical trial, Medication

Post navigation

Previous PostPrevious A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
Next PostNext An unrecognized mode of small particles in the lower stratosphere

This is the footer

Privacy Policy Proudly powered by WordPress